Now showing items 3390-3409 of 4758

    • Prostate-specific Membrane Antigen Heterogeneity and DNA Repair Defects in Prostate Cancer. 

      Paschalis, A; Sheehan, B; Riisnaes, R; Rodrigues, DN; Gurel, B; Bertan, C; Ferreira, A; Lambros, MBK; Seed, G; Yuan, W; Dolling, D; Welti, JC; Neeb, A; Sumanasuriya, S; Rescigno, P; Bianchini, D; Tunariu, N; Carreira, S; Sharp, A; Oyen, W; de Bono, JS (2019-10)
      Background Prostate-specific membrane antigen (PSMA; folate hydrolase) prostate cancer (PC) expression has theranostic utility. Objective To elucidate PC PSMA expression and associate this with defective DNA damage repair ...
    • Prostatic pathology reporting in the UK: development of a national external quality assurance scheme 

      Harnden, P; Coleman, D; Moss, S; Kodikara, S; Patnick, J; Melia, J (BLACKWELL PUBLISHING, 2008-01)
      Aims: To develop a baseline picture of prostatic pathology reporting in the UK, identify areas of particular difficulty and assess the feasibility of a national external quality assurance scheme based on prostatic biopsy ...
    • Proteasomal degradation of the tumour suppressor FBW7 requires branched ubiquitylation by TRIP12. 

      Khan, OM; Almagro, J; Nelson, JK; Horswell, S; Encheva, V; Keyan, KS; Clurman, BE; Snijders, AP; Behrens, A (2021-04-06)
      The tumour suppressor FBW7 is a substrate adaptor for the E3 ubiquitin ligase complex SKP1-CUL1-F-box (SCF), that targets several oncoproteins for proteasomal degradation. FBW7 is widely mutated and FBW7 protein levels are ...
    • Protein and drug interactions in the minor groove of DNA 

      Moravek, Z; Neidle, S; Schneider, B (2002-03-01)
      Interactions between proteins, drugs, water and B-DNA minor groove have been analyzed in crystal structures of 60 protein-DNA and 14 drug-DNA complexes. It was found that only purine N3, pyrimidine O2, guanine N2 and ...
    • Protein assemblies with palindromic structure motifs 

      Pinotsis, N; Wilmanns, M (BIRKHAUSER VERLAG AG, 2008-10)
      Symmetric DNA sequence motifs allow the formation of palindromic protein/DNA complexes. Although symmetric protein sequence motifs are less common, recent structural discoveries have unraveled a few protein/protein complexes ...
    • Protein coalitions in a core mammalian biochemical network linked by rapidly evolving proteins 

      Ainali, C; Simon, M; Freilich, S; Espinosa, O; Hazelwood, L; Tsoka, S; Ouzounis, CA; Hancock, JM (BIOMED CENTRAL LTD, 2011-05-25)
      Background: Cellular ATP levels are generated by glucose-stimulated mitochondrial metabolism and determine metabolic responses, such as glucose-stimulated insulin secretion (GSIS) from the beta-cells of pancreatic islets. ...
    • Protein identification and quantification by two-dimensional infrared spectroscopy: Implications for an all-optical proteomic platform 

      Fournier, F; Gardner, EM; Kedra, DA; Donaldson, PM; Guo, R; Butcher, SA; Gould, IR; Willison, KR; Klug, DR (NATL ACAD SCIENCES, 2008-10-07)
      Electron-vibration-vibration two-dimensional coherent spectroscopy, a variant of 2DIR, is shown to be a useful tool to differentiate a set of 10 proteins based on their amino acid content. Two-dimensional vibrational ...
    • Protein-altering germline mutations implicate novel genes related to lung cancer development. 

      Ji, X; Mukherjee, S; Landi, MT; Bosse, Y; Joubert, P; Zhu, D; Gorlov, I; Xiao, X; Han, Y; Gorlova, O; Hung, RJ; Brhane, Y; Carreras-Torres, R; Christiani, DC; Caporaso, N; Johansson, M; Liu, G; Bojesen, SE; Le Marchand, L; Albanes, D; Bickeböller, H; Aldrich, MC; Bush, WS; Tardon, A; Rennert, G; Chen, C; Byun, J; Dragnev, KH; Field, JK; Kiemeney, LF; Lazarus, P; Zienolddiny, S; Lam, S; Schabath, MB; Andrew, AS; Bertazzi, PA; Pesatori, AC; Diao, N; Su, L; Song, L; Zhang, R; Leighl, N; Johansen, JS; Mellemgaard, A; Saliba, W; Haiman, C; Wilkens, L; Fernandez-Somoano, A; Fernandez-Tardon, G; Heijden, EHFMVD; Kim, JH; Davies, MPA; Marcus, MW; Brunnström, H; Manjer, J; Melander, O; Muller, DC; Overvad, K; Trichopoulou, A; Tumino, R; Goodman, GE; Cox, A; Taylor, F; Woll, P; Wichmann, E; Muley, T; Risch, A; Rosenberger, A; Grankvist, K; Johansson, M; Shepherd, F; Tsao, M-S; Arnold, SM; Haura, EB; Bolca, C; Holcatova, I; Janout, V; Kontic, M; Lissowska, J; Mukeria, A; Ognjanovic, S; Orlowski, TM; Scelo, G; Swiatkowska, B; Zaridze, D; Bakke, P; Skaug, V; Butler, LM; Offit, K; Srinivasan, P; Bandlamudi, C; Hellmann, MD; Solit, DB; Robson, ME; Rudin, CM; Stadler, ZK; Taylor, BS; Berger, MF; Houlston, R; McLaughlin, J; Stevens, V; Nickle, DC; Obeidat, M; Timens, W; Artigas, MS; Shete, S; Brenner, H; Chanock, S; Brennan, P; McKay, JD; Amos, CI (2020-05-11)
      Few germline mutations are known to affect lung cancer risk. We performed analyses of rare variants from 39,146 individuals of European ancestry and investigated gene expression levels in 7,773 samples. We find a large-effect ...
    • Proteogenomics of Non-smoking Lung Cancer in East Asia Delineates Molecular Signatures of Pathogenesis and Progression. 

      Chen, Y-J; Roumeliotis, TI; Chang, Y-H; Chen, C-T; Han, C-L; Lin, M-H; Chen, H-W; Chang, G-C; Chang, Y-L; Wu, C-T; Lin, M-W; Hsieh, M-S; Wang, Y-T; Chen, Y-R; Jonassen, I; Ghavidel, FZ; Lin, Z-S; Lin, K-T; Chen, C-W; Sheu, P-Y; Hung, C-T; Huang, K-C; Yang, H-C; Lin, P-Y; Yen, T-C; Lin, Y-W; Wang, J-H; Raghav, L; Lin, C-Y; Chen, Y-S; Wu, P-S; Lai, C-T; Weng, S-H; Su, K-Y; Chang, W-H; Tsai, P-Y; Robles, AI; Rodriguez, H; Hsiao, Y-J; Chang, W-H; Sung, T-Y; Chen, J-S; Yu, S-L; Choudhary, JS; Chen, H-Y; Yang, P-C; Chen, Y-J (2020-07)
      Lung cancer in East Asia is characterized by a high percentage of never-smokers, early onset and predominant EGFR mutations. To illuminate the molecular phenotype of this demographically distinct disease, we performed a ...
    • Proteomic analysis of extracellular vesicles from a <i>Plasmodium falciparum</i> Kenyan clinical isolate defines a core parasite secretome. 

      Abdi, A; Yu, L; Goulding, D; Rono, MK; Bejon, P; Choudhary, J; Rayner, J (2017-01)
      Background Many pathogens secrete effector molecules to subvert host immune responses, to acquire nutrients, and/or to prepare host cells for invasion. One of the ways that effector molecules are secreted is through ...
    • Proteomic analysis of extracellular vesicles from a Plasmodium falciparum Kenyan clinical isolate defines a core parasite secretome 

      Abdi, A; Yu, L; Goulding, D; Rono, M; Bejon, P; Choudhary, J; Rayner, J (2017-11-22)
      Background : Many pathogens secrete effector molecules to subvert host immune responses, to acquire nutrients, and/or to prepare host cells for invasion. One of the ways that effector molecules are secreted is through ...
    • Proteomic navigation using proximity-labeling. 

      Gentzel, M; Pardo, M; Subramaniam, S; Stewart, AF; Choudhary, JS (2019-07)
      The identification of bona fide protein-protein interactions and the mapping of proteomes was greatly enhanced by protein tagging for generic affinity purification methods and analysis by mass spectrometry (AP-MS). The ...
    • Proteomic profiling of soft tissue sarcomas with SWATH mass spectrometry. 

      Milighetti, M; Krasny, L; Lee, ATJ; Morani, G; Szecsei, C; Chen, Y; Guljar, N; McCarthy, F; Wilding, CP; Arthur, A; Fisher, C; Judson, I; Thway, K; Cheang, MCU; Jones, RL; Huang, PH
      Soft tissue sarcomas (STS) are a group of rare and heterogeneous cancers. While large-scale genomic and epigenomic profiling of STS have been undertaken, proteomic analysis has thus far been limited. Here we utilise ...
    • Proteomic research in sarcomas - current status and future opportunities. 

      Burns, J; Wilding, CP; L Jones, R; H Huang, P (2020-04)
      Sarcomas are a rare group of mesenchymal cancers comprising over 70 different histological subtypes. For the majority of these diseases, the molecular understanding of the basis of their initiation and progression remains ...
    • Proteomics and the search for biomarkers for renal cancer 

      Craven, RA; Vasudev, NS; Banks, RE (PERGAMON-ELSEVIER SCIENCE LTD, 2013-04)
      Worldwide, over 273,000 people are diagnosed with renal cancer each year. Approximately one third of patients present with locally advanced or metastatic disease and although surgery is largely curative in those with ...
    • Proteomics of REPLICANT perfusate detects changes in the metastatic lymph node microenvironment. 

      Stevenson, J; Barrow-McGee, R; Yu, L; Paul, A; Mansfield, D; Owen, J; Woodman, N; Natrajan, R; Haider, S; Gillett, C; Tutt, A; Pinder, SE; Choudary, J; Naidoo, K (2021-03-05)
      In breast cancer (BC), detecting low volumes of axillary lymph node (ALN) metastasis pre-operatively is difficult and novel biomarkers are needed. We recently showed that patient-derived ALNs can be sustained ex-vivo using ...
    • Proteomics profiling of interactome dynamics by colocalisation analysis (COLA). 

      Mardakheh, FK; Sailem, HZ; Kümper, S; Tape, CJ; McCully, RR; Paul, A; Anjomani-Virmouni, S; Jørgensen, C; Poulogiannis, G; Marshall, CJ; Bakal, C (2016-12)
      Localisation and protein function are intimately linked in eukaryotes, as proteins are localised to specific compartments where they come into proximity of other functionally relevant proteins. Significant co-localisation ...
    • Protocol for hypofractionated adaptive radiotherapy to the bladder within a multicentre phase II randomised trial: radiotherapy planning and delivery guidance. 

      Hafeez, S; Patel, E; Webster, A; Warren-Oseni, K; Hansen, V; McNair, H; Miles, E; Lewis, R; Hall, E; Huddart, R (2020-05-26)
      INTRODUCTION:Patients with muscle invasive bladder cancer (MIBC) who are unfit and unsuitable for standard radical treatment with cystectomy or daily radiotherapy present a large unmet clinical need. Untreated, they suffer ...
    • Protocol for tumour-focused dose-escalated adaptive radiotherapy for the radical treatment of bladder cancer in a multicentre phase II randomised controlled trial (RAIDER): radiotherapy planning and delivery guidance. 

      Hafeez, S; Webster, A; Hansen, VN; McNair, HA; Warren-Oseni, K; Patel, E; Choudhury, A; Creswell, J; Foroudi, F; Henry, A; Kron, T; McLaren, DB; Mitra, AV; Mostafid, H; Saunders, D; Miles, E; Griffin, C; Lewis, R; Hall, E; Huddart, R (2020-12-31)
      Introduction Daily radiotherapy delivered with radiosensitisation offers patients with muscle invasive bladder cancer (MIBC) comparable outcomes to cystectomy with functional organ preservation. Most recurrences following ...
    • Proton Beam Therapy - the Challenges of Delivering High-quality Evidence of Clinical Benefit. 

      National Cancer Research Institute Clinical and Translational Radiotherapy Research Working Group (CTRad) Proton Beam Clinical Trial Strategy Group (2018-05)
      The use of proton beam therapy (PBT) offers the opportunity to improve greater conformality of radiotherapy treatment delivery in some patients. However, it is associated with a high capital cost and the need to build new ...